Real-time enrollment status for this pik3ca-related overgrowth spectrum (pros) clinical trial
Current Status
Recruiting
Checked: August 27, 2026 at 5:54 PM UTC
| NCT Number | NCT06997588 |
| Recruiting Status | Recruiting |
| Condition | PIK3CA-related Overgrowth Spectrum (PROS) |
| Phase | PHASE2 |
| Target Enrollment | 104 participants |
| Active Locations | 8 sites in the US |
| Sponsor | Novartis Pharmaceuticals |
| Last Updated on CT.gov | August 18, 2026 (1 week ago) |
As of August 27, 2026: Clinical trial NCT06997588 is currently recruiting participants. This phase2 study for pik3ca-related overgrowth spectrum (pros) is actively seeking new participants at 8 locations across the United States. The study is sponsored by Novartis Pharmaceuticals. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT06997588 is actively recruiting participants as of August 27, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 8 locations in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT06997588 was last updated 1 week ago (August 18, 2026). HelloStudys verifies this status automatically.